Moxalactam treatment of serious infections primarily due to Haemophilus influenzae type b in children.

Thirty-eight children completed therapy with moxalactam for a variety of non-CNS infections. Haemophilus influenzae type b (seven ampicillin-resistant strains) was the etiologic agent for 32 children. Doses of moxalactam ranged from 113 to 200 mg/kg/d in three or four divided doses administered parenterally.

Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience.

Over a 3-year period, 96% of systemic infections in children caused by Haemophilus influenzae were of serotype b. Of 346 invasive infections, 15 (4%) were caused by non-type b H. influenzae.

Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.

The serum pharmacokinetics and CSF penetration of moxalactam were determined in 39 children with bacterial meningitis. The mean serum concentrations 30 minutes after a 37.5 or 50 mg/kg dose were 66.